Request Demo
Last update 11 Mar 2026
GenSci139
Last update 11 Mar 2026
Overview
Basic Info
Drug Type Antibody drug conjugate (ADC) |
Synonyms GenSci-139 |
Target |
Action antagonists, inhibitors |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Boost your research with our ADC technology data.
login
or
Related
1
Clinical Trials associated with GenSci139NCT07230977
A Phase I, Two-Part, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activities of GenSci139 in Patients With Locally Advanced or Metastatic Solid Tumors
100 Clinical Results associated with GenSci139
Login to view more data
100 Translational Medicine associated with GenSci139
Login to view more data
100 Patents (Medical) associated with GenSci139
Login to view more data
100 Deals associated with GenSci139
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | China | 19 Nov 2025 | |
| Advanced Malignant Solid Neoplasm | IND Approval | China | 21 Oct 2025 | |
| Non-Small Cell Lung Cancer | Preclinical | China | 16 Jan 2026 | |
| Small Cell Lung Cancer | Preclinical | China | 16 Jan 2026 | |
| Breast Cancer | Preclinical | China | 27 Apr 2025 | |
| Colorectal Cancer | Preclinical | China | 27 Apr 2025 | |
| Lung Cancer | Preclinical | China | 27 Apr 2025 | |
| Ovarian Cancer | Preclinical | China | 27 Apr 2025 | |
| Stomach Cancer | Preclinical | China | 27 Apr 2025 | |
| Transitional Cell Carcinoma | Preclinical | China | 27 Apr 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free